Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ

2014 ◽  
Vol 32 (22) ◽  
pp. 2373-2379 ◽  
Author(s):  
Richard L. Schilsky ◽  
Dina L. Michels ◽  
Amy H. Kearbey ◽  
Peter Paul Yu ◽  
Clifford A. Hudis
Keyword(s):  
Health Care ◽  
Big Data ◽  
Quality Care ◽  
Quality Measurement ◽  
New Drugs ◽  
Large Numbers ◽  
New Information ◽  
American Society ◽  
Clinical Records ◽  
The Cost

Today is a time of unprecedented opportunity and challenge in health care generally and cancer care in particular. An explosion of scientific knowledge, the rapid introduction of new drugs and technologies, and the unprecedented escalation in the cost of health care challenge physicians to quickly assimilate new information and appropriately deploy new advances while also delivering efficient and high-quality care to a rapidly growing and aging patient population. At the same time, big data, with its potential to drive rapid understanding and innovation, promises to transform the health care industry, as it has many others already. CancerLinQ is an initiative of the American Society of Clinical Oncology (ASCO) and its Institute for Quality, developed to build on these opportunities and address these challenges by collecting information from the electronic health records of large numbers of patients with cancer. CancerLinQ is, first and foremost, a quality measurement and reporting system through which oncologists can harness the depth and power of their patients' clinical records and other data to improve the care they deliver. The development and deployment of CancerLinQ raises many important questions about the use of big data in health care. This article focuses on the US federal regulatory pathway by which CancerLinQ will accept patient records and the approach of ASCO toward stewardship of the information.

scholarly journals A Survey on Securing and Optimizing Health Care Bigdata

2018 ◽  
Vol 7 (4.10) ◽  
pp. 504
Author(s):  
K. Kavitha ◽  
D. Anuradha ◽  
P. Pandian
Keyword(s):  
Health Care ◽  
Big Data ◽  
Access Control ◽  
Mathematical Optimization ◽  
Optimization Techniques ◽  
Role Based Access Control ◽  
Attribute Based Access Control ◽  
Optimization And Simulation ◽  
Role Based ◽  
The Cost

Huge amount of health care data are available online to improve the overall performance of health care system. Since this huge health care Big-data is valuable and sensitive, it requires safety. In this paper we analyze numerous ways in which the health care Big-data can be protected. In recent days many augmented security algorithm that are suitable for Big-data have emerged like, El-Gamal, Triple-DES, and Homomorphic algorithms. Also authentication and access control can be implemented over Big-data using Role-Based Access Control (RBAC) and Attribute-Based Access Control (ABAC) schemes.Along with security to Big-data we try to evolve the ways in which the valuable Big-data can be optimized to improve the Big-data analysis. Mathematical optimization techniques such as simple and multi-purpose optimization and simulation are employed in Big-data to maximize the patient satisfaction and usage of doctor’s consulting facility. And also, to minimize the cost spent by patient and energy wasted.  

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

2009 ◽  
Vol 27 (23) ◽  
pp. 3868-3874 ◽  
Author(s):  
Neal J. Meropol ◽  
Deborah Schrag ◽  
Thomas J. Smith ◽  
Therese M. Mulvey ◽  
Robert M. Langdon ◽  
...  
Keyword(s):  
United States ◽  
Health Care ◽  
Clinical Oncology ◽  
Cancer Care ◽  
Cost Effective ◽  
The United States ◽  
Cost Of Care ◽  
High Quality ◽  
American Society ◽  
The Cost

Advances in early detection, prevention, and treatment have resulted in consistently falling cancer death rates in the United States. In parallel with these advances have come significant increases in the cost of cancer care. It is well established that the cost of health care (including cancer care) in the United States is growing more rapidly than the overall economy. In part, this is a result of the prices and rapid uptake of new agents and other technologies, including advances in imaging and therapeutic radiology. Conventional understanding suggests that high prices may reflect the costs and risks associated with the development, production, and marketing of new drugs and technologies, many of which are valued highly by physicians, patients, and payers. The increasing cost of cancer care impacts many stakeholders who play a role in a complex health care system. Our patients are the most vulnerable because they often experience uneven insurance coverage, leading to financial strain or even ruin. Other key groups include pharmaceutical manufacturers that pass along research, development, and marketing costs to the consumer; providers of cancer care who dispense increasingly expensive drugs and technologies; and the insurance industry, which ultimately passes costs to consumers. Increasingly, the economic burden of health care in general, and high-quality cancer care in particular, will be less and less affordable for an increasing number of Americans unless steps are taken to curb current trends. The American Society of Clinical Oncology (ASCO) is committed to improving cancer prevention, diagnosis, and treatment and eliminating disparities in cancer care through support of evidence-based and cost-effective practices. To address this goal, ASCO established a Cost of Care Task Force, which has developed this Guidance Statement on the Cost of Cancer Care. This Guidance Statement provides a concise overview of the economic issues facing stakeholders in the cancer community. It also recommends that the following steps be taken to address immediate needs: recognition that patient-physician discussions regarding the cost of care are an important component of high-quality care; the design of educational and support tools for oncology providers to promote effective communication about costs with patients; and the development of resources to help educate patients about the high cost of cancer care to help guide their decision making regarding treatment options. Looking to the future, this Guidance Statement also recommends that ASCO develop policy positions to address the underlying factors contributing to the increased cost of cancer care. Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care.

scholarly journals SURVEY ON ACCURACY OF PREDICTIVE BIG DATA ANALYTICS IN HEALTHCARE

2019 ◽  
Vol 01 (02) ◽  
pp. 77-86
Author(s):  
Smys S
Keyword(s):  
Health Care ◽  
Big Data ◽  
Data Analytics ◽  
New Technologies ◽  
Big Data Analytics ◽  
Health Care Industry ◽  
Research Area ◽  
Care Industry ◽  
The Core ◽  
The Cost

The failures in the most of research area, identified that the lack of details about the actionable and the valuable data that conceived actual solutions were the core of the crisis, this was very true in case of the health care industry where even the early diagnoses of a chronic disease could not save a person’s life. This because of the impossibility in the prediction of the individual’s outcomes in the entire population. The evolving new technologies have changed this scenario leveraging the mobile devices and the internet services such as the sensor network and the smart monitors, enhancing the practical healthcare using the predictive modeling acquiring a deeper individual measures. This affords the researches to go through the huge set of data and identify the patterns along with the trends and delivering solutions improvising the medical care, minimizing the cost and he regulating the health admittance, ensuring the safety of human lives. The paper provides the survey on the predictive big data analysis and accuracy it provides in the health care system.

Economics of Schizophrenia

1995 ◽  
Vol 40 (7_suppl) ◽  
pp. 60-67 ◽  
Author(s):  
Richard Williams ◽  
Ruth A Dickson
Keyword(s):  
Health Care ◽  
Cost Savings ◽  
Cost Effective ◽  
Health Care Expenditures ◽  
Mental Illnesses ◽  
New Drugs ◽  
Special Treatment ◽  
Lengths Of Stay ◽  
The Us ◽  
The Cost

Objective: To discuss the costs associated with mental illnesses that constitute a significant percentage of the total direct health care costs, currently estimated at $1605 per person per year (9% of the gross national product). The cost of all mental illness in the US has been estimated at US$103.7 billion (1985 dollars), of which schizophrenia alone accounts for US$22.7 billion. Method: A number of studies that have attempted to evaluate the cost of therapies in schizophrenia are examined. Results: While schizophrenia affects only 1% of the population, it accounts for 2.5% of total health care expenditures in the US. For first-admission patients suffering from schizophrenia, it would appear to cost less to provide the most clinically-effective treatments than to provide a good level of milieu care with special treatment. Conclusion: Community-based care can be less costly than conventional hospital-based programs and can improve patient quality of life. Inhospital programs that reduce length of stay with the use of medication clinics or day hospital care may achieve significant cost savings. A special challenge is the subgroup of patients suffering from schizophrenia that is neuroleptic-resistant. New drugs, such as the atypical neuroleptics, clozapine and risperidone, may prove to be highly cost-effective in treating schizophrenia by preventing relapse and reducing hospital lengths of stay.

Building castles on sands or quicksands?

1998 ◽  
Vol 173 (S36) ◽  
pp. 12-18 ◽  
Author(s):  
Alan Maynard ◽  
Karen Bloor
Keyword(s):  
Health Care ◽  
Health Care Systems ◽  
Pharmaceutical Products ◽  
New Drugs ◽  
Economic Evaluations ◽  
Therapeutic Effects ◽  
Treatment Of Depression ◽  
Care Systems ◽  
Essential Input ◽  
The Cost

Economic evaluations of new and existing pharmaceutical products are an essential input into decision-making in health care. Health care systems around the world face steady increases in the total cost of pharmaceuticals. Increasingly, health care funders have to choose which drugs are subsidised and which are not reimbursed from public funds. In psychiatry, a number of new pharmaceutical products have recently been developed for the treatment of depression and schizophrenia which cost considerably more than traditional pharmacological products. Governments and purchasers, with limited budgets and expanded demands for funding, require pharmaceutical companies to demonstrate the cost-effectiveness of their new therapies. It is no longer sufficient to consider the clinical or therapeutic effects of new drugs: purchasing choices are predicted on studies which identify, measure and value what is given up when a product is used (the cost) and what is gained (improved health outcome).

scholarly journals SURVEY ON ACCURACY OF PREDICTIVE BIG DATA ANALYTICS IN HEALTHCARE

2019 ◽  
Vol 01 (02) ◽  
pp. 77-86
Author(s):  
Smys S
Keyword(s):  
Health Care ◽  
Big Data ◽  
Data Analytics ◽  
New Technologies ◽  
Big Data Analytics ◽  
Health Care Industry ◽  
Research Area ◽  
Care Industry ◽  
The Core ◽  
The Cost

The failures in the most of research area, identified that the lack of details about the actionable and the valuable data that conceived actual solutions were the core of the crisis, this was very true in case of the health care industry where even the early diagnoses of a chronic disease could not save a person’s life. This because of the impossibility in the prediction of the individual’s outcomes in the entire population. The evolving new technologies have changed this scenario leveraging the mobile devices and the internet services such as the sensor network and the smart monitors, enhancing the practical healthcare using the predictive modeling acquiring a deeper individual measures. This affords the researches to go through the huge set of data and identify the patterns along with the trends and delivering solutions improvising the medical care, minimizing the cost and he regulating the health admittance, ensuring the safety of human lives. The paper provides the survey on the predictive big data analysis and accuracy it provides in the health care system.

scholarly journals Antimicrobial Prophylaxis for Caesarean Delivery; A comparative study between different agents

2021 ◽  
Vol 20 (1) ◽  
pp. 1-10
Author(s):  
Afroditi Ziogou ◽  
Ioannis Kokolakis ◽  
Fanourios Makrygiannakis ◽  
Antonis Makrigiannakis
Keyword(s):  
Health Care ◽  
Hospital Stay ◽  
Caesarean Delivery ◽  
Antimicrobial Prophylaxis ◽  
Pelvic Abscess ◽  
Surgical Interventions ◽  
Pelvic Vein ◽  
Puerperal Infection ◽  
American Society ◽  
The Cost

Antimicrobial prophylaxis is commonly used for pre-intra and post-operative caesarean delivery. Caesarean delivery is still the single most important risk factor for puerperal infection. Post-caesarean infections include wound infections, endomyometritis, bacteraemia, septic shock, septic pelvic vein thrombophlebitis, necrotising fasciitis, pelvic abscess, dehiscence of the wound or evisceration. The goal of antimicrobial prophylaxis is to put a stop to postoperative infection of the surgical site, the use of therapeutic antibiotics, additional surgical interventions, longer duration of hospital stay, to decrease postoperative infectious morbidity and mortality and the cost of postoperative health care. A post-caesarean wound infection detected prior to hospital discharge will lead to prolongation of hospital stay and will increase the hospitalisation costs and need of readmission. Both the American College of Obstetricians and Gynaecologists and the American Society of Health-Care System Pharmacists have introduced single-dose prophylactic protocols using a heterogeneity of agents (penicillins, cephalosporins, clindamycin and azithromycin). Women undergoing caesarean delivery have a greater risk of developing infection compared to women who have a vaginal birth by 5 to 20-fold. The use of prophylaxis in patients undergoing a low-risk Caesarean Delivery remains controversial.

scholarly journals American Society of Clinical Oncology Quality Care Symposium 2012: Re-Engineering Your Practice to Deliver Quality and Value

2013 ◽  
Vol 9 (3) ◽  
pp. 160-161 ◽  
Author(s):  
Robert D. Siegel
Keyword(s):  
Health Care ◽  
Clinical Oncology ◽  
Delivery System ◽  
Health Care Delivery ◽  
Care Delivery ◽  
Quality Care ◽  
Health Care Delivery System ◽  
Reliable System ◽  
American Society ◽  
Efficient Care

This session highlighted the steps in creating a reliable system-based health care delivery system—one that is team based, is continually evolving, and provides the highest quality and efficient care for our patients.

scholarly journals The effectiveness of medical care to patients with asthma in Tomsk Region

2011 ◽  
Vol 10 (1) ◽  
pp. 174-178
Author(s):  
O. S. Kobyakova ◽  
L. M. Ogorodova ◽  
L. V. Abashina ◽  
I. A. Deyev ◽  
E. A. Starovoytova
Keyword(s):  
Health Care ◽  
Emergency Care ◽  
Statistical Study ◽  
Quality Care ◽  
Significant Progress ◽  
Asthmatic Patients ◽  
Cost Of Health Care ◽  
Tomsk Region ◽  
Chronic Morbidity ◽  
The Cost

A statistical study of indicators of primary and chronic morbidity, mortality, clinical examinations, emergency care, the level of hospitalization of patients with asthma in the Tomsk Region for the years 1998—2008 was performed. This study used data of 843 thousand inhabitants of the Tomsk Region in the age of 18 years.During 1998—2008 in the Tomsk Region has made significant progress in the conduct of asthmatic patients, which is reflected in the cost of health care and higher quality care this patient.

The Cost of Health Care — Highlights from a Discussion about Economics and Reform

2009 ◽  
Vol 361 (15) ◽  
pp. 1421-1423 ◽  
Author(s):  
Atul A. Gawande ◽  
Elliott S. Fisher ◽  
Jonathan Gruber ◽  
Meredith B. Rosenthal
Keyword(s):  
Health Care ◽  
Cost Of Health Care ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document